SST001, an -syn PET tracer from Mabwell's incubated company SynuSight Biotech, received NMPA approval to initiate a clinical trial Accessibility StatementSkip Navigation SHANGHAI, April 14, 2026 /PRNewswire/ -- Mabwell (688062.SH), an innovation-driven biopharmaceutical company with a fully integrated industry chain, announced that 18F-FD4 (R&D code: SST001), an -synuclein (- syn) targeted PET tracer independently developed by its incubated company SynuSight Biotech, has recently been approved by the Nation ...